Health Care • Other Pharmaceuticals
$4.65 ▼ -0.04
(-0.85%)
MKT CAP: $228.3M • VOL: 351.5K
52W L $4 52W H $12
NUS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.49B | $1.73B | $1.97B |
| YoY Revenue Growth % | -14.3% | -12.0% | — |
| Gross Profit | $1.03B | $1.18B | — |
| Gross Margin % | 69.4% | 68.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $65.8M | -$151.6M | $48.3M |
| Operating Margin % | 4.4% | -8.8% | 2.5% |
| Net Income (GAAP) | $160.2M | -$146.6M | $8.6M |
| EBITDA (Normalized) | $93.2M | -$118.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $80.3M | $111.7M | $118.6M |
| Capital Expenditures (CapEx) | $34.3M | $41.6M | — |
| Free Cash Flow (FCF) | $46.0M | $70.2M | $118.6M |
| FCF Margin % | 3.1% | 4.1% | 6.0% |
| Return on Invested Capital (ROIC %) | 6.7% | -14.5% | — |
| Cash & Short-Term Equivalents | $238.6M | $186.9M | — |
| Total Debt (Short + Long Term) | $204.2M | $363.6M | — |
| Total Stockholders' Equity | $805.2M | $651.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NUS.